Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 10
2003 16
2004 12
2005 18
2006 13
2007 13
2008 17
2009 11
2010 14
2011 22
2012 19
2013 22
2014 26
2015 24
2016 31
2017 35
2018 30
2019 33
2020 40
2021 52
2022 46
2023 50
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

508 results

Results by year

Filters applied: . Clear all
Page 1
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Dreyling M, et al. Among authors: zinzani pl. Lancet. 2024 May 2:S0140-6736(24)00184-3. doi: 10.1016/S0140-6736(24)00184-3. Online ahead of print. Lancet. 2024. PMID: 38705160
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity.
Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A, Gori D, Masetti R, Stefoni V, Bonifazi F, Zinzani PL, Argnani L. Di Staso R, et al. Among authors: zinzani pl. Ann Hematol. 2024 May 2. doi: 10.1007/s00277-024-05766-0. Online ahead of print. Ann Hematol. 2024. PMID: 38695872
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review.
Criscuolo M, Tosti ME, Broccoli A, Varettoni M, Maraglino AME, Anastasia A, Cantonetti M, Trentin L, Kovalchuk S, Orsucci L, Deodato M, Spolzino A, Volpetti S, Annibali O, Storti S, Stelitano C, Marchesi F, Morè S, Fianchi L, Falini B, Pulsoni A, Tiacci E, Zinzani PL, Pagano L. Criscuolo M, et al. Among authors: zinzani pl. Cancers (Basel). 2024 Apr 11;16(8):1475. doi: 10.3390/cancers16081475. Cancers (Basel). 2024. PMID: 38672557 Free PMC article.
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy.
Pensato U, Pondrelli F, de Philippis C, Asioli GM, Crespi A, Buizza A, Mannina D, Casadei B, Maffini E, Straffi L, Marcheselli S, Zinzani PL, Bonifazi F, Guarino M, Bramanti S. Pensato U, et al. Among authors: zinzani pl. Neurol Sci. 2024 Apr 4. doi: 10.1007/s10072-024-07510-y. Online ahead of print. Neurol Sci. 2024. PMID: 38573433 No abstract available.
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Zinzani PL, Salles GA, Moskowitz AJ, Santoro A, Mehta A, Barr PM, Mehta-Shah N, Collins GP, Ansell SM, Brody JD, Domingo-Domenech E, Johnson NA, Cunningham D, Ferrari S, Lisano JM, Krajewski J, Wen R, Akyol A, Crowe R, Savage KJ. Zinzani PL, et al. Blood Adv. 2024 Mar 26:bloodadvances.2023011030. doi: 10.1182/bloodadvances.2023011030. Online ahead of print. Blood Adv. 2024. PMID: 38531062 No abstract available.
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy.
Pensato U, Pondrelli F, de Philippis C, Asioli GM, Crespi A, Buizza A, Mannina D, Casadei B, Maffini E, Straffi L, Marcheselli S, Zinzani PL, Bonifazi F, Guarino M, Bramanti S. Pensato U, et al. Among authors: zinzani pl. Neurol Sci. 2024 Mar 21. doi: 10.1007/s10072-024-07481-0. Online ahead of print. Neurol Sci. 2024. PMID: 38512531
Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis.
Driessen J, de Wit F, Herrera AF, Zinzani PL, LaCasce AS, Cole PD, Moskowitz CH, García-Sanz R, Fuchs M, Mueller H, Borchmann P, Santoro A, Schöder H, Zijlstra JM, Hutten BA, Moskowitz AJ, Kersten MJ. Driessen J, et al. Among authors: zinzani pl. Blood Adv. 2024 Mar 19:bloodadvances.2023012145. doi: 10.1182/bloodadvances.2023012145. Online ahead of print. Blood Adv. 2024. PMID: 38502227
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AM, Cutini I, Dodero A, Bonifazi F, Tisi MC, Bramanti S, Musso M, Farina M, Martino M, Novo M, Grillo G, Patriarca F, Zacchi G, Krampera M, Pennisi M, Galli E, Martelli M, Ferreri AJM, Ferrari S, Saccardi R, Bermema A, Guidetti A, Miceli R, Zinzani PL, Corradini P. Chiappella A, et al. Among authors: zinzani pl. Leukemia. 2024 May;38(5):1107-1114. doi: 10.1038/s41375-024-02213-x. Epub 2024 Mar 8. Leukemia. 2024. PMID: 38459167
508 results